Application of desktop bioreactor in laboratory
05,11,2026 83 views
Recently,Tianjin Zhonghe Gene Technology Co., Ltd. has received another investment of 10 million yuan from Tianjin Tiankai Hongda Taida Haihe Entrepreneurship Investment Fund Partnership Enterprise (Limited Partnership).This capital injection not only recognizes the company's technological barriers and industrialization potential in the capital market, but also injects sufficient impetus into the technological upgrading and large-scale promotion of domestically produced biological DNA synthesis equipment.
Zhonghe Gene was founded in 2022 and is headquartered in Tianjin. It is a high-tech enterprise that focuses on enzymatic DNA biosynthesis technology as its core, specializing in the research and development, production, and sales of DNA synthesis equipment, supporting reagents, and synthesis services. We always strive to break through the bottleneck of traditional chemical synthesis technology and achieve high-end life sciencesinstrumentDomestic substitution is the development goal, and the products are widely used in cutting-edge fields such as synthetic biology, biomedicine, basic scientific research, and DNA information storage. The company has built a research and development base of over a thousand square meters, with a core R&D team that holds nearly 40% of master's and doctoral degrees. It has accumulated more than 40 core intellectual property rights and has been awarded qualifications such as National High tech Enterprise and Tianjin Specialized, Refined, Special and New Small and Medium sized Enterprise. It has established deep cooperation with multiple domestic research institutes and industrial enterprises.
Relying on its full stack independent research and development capabilities, Zhonghe Gene has formed a complete product matrix in the field of enzymatic DNA synthesis. Its core product TIESyno ®- The 96 DNA biosynthetic instrument and automated gene splicing instrument are equipped with independently developed enzymatic synthesis processes, with core technical indicators at the international leading level. They can achieve green, efficient, and low-cost gene synthesis in conventional experimental environments, breaking through many limitations of traditional chemical synthesis methods in terms of growth rate, environmental friendliness, and cost. At present, the company is accelerating the research and development of Kb level gene synthesizers, further improving the high-end product lineup, and meeting the scientific research and industrial needs for longer fragment gene synthesis.
This round of financing funds will focus on three major directions to promote business layout: first, continuous iteration of TIESyno ® The product performance of the series of DNA biosynthetic instruments accelerates the research and development and implementation of Kb level gene synthesizers, consolidating the technological leading advantage; The second is to improve the construction of automated production system, enhance the mass production capacity and delivery efficiency of equipment and supporting reagents; The third is to deepen the market layout in core fields such as synthetic biology and biomedicine, improve the customer service system, and expand the market coverage of domestic DNA synthesis equipment.
The implementation of this financing will promote the technological iteration and capacity release of Zhonghe Gene in the field of biological DNA synthesis equipment, accelerate the domestic substitution process of high-end life science instruments, and provide solid underlying equipment support for the independent development of China's cutting-edge industries such as synthetic biology.
Risk Warning: The content of this article comes from a third party and is intended to disseminate information. It does not represent the position of this platform and does not constitute any investment advice. Investors should make independent judgments based on official announcements and bear investment risks on their own.
